These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 19900982)

  • 1. Bilateral retinal vasculitis in a patient with systemic lupus erythematosus and its remission with rituximab therapy.
    Hickman RA; Denniston AK; Yee CS; Toescu V; Murray PI; Gordon C
    Lupus; 2010 Mar; 19(3):327-9. PubMed ID: 19900982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of cold agglutinin disease with anti-CD20 antibody (rituximab) in a patient with systemic lupus erythematosus.
    Kotani T; Takeuchi T; Kawasaki Y; Hirano S; Tabushi Y; Kagitani M; Makino S; Hanafusa T
    Lupus; 2006; 15(10):683-5. PubMed ID: 17120596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of inflammatory immunologic disease 4. B cell targeting therapy using the anti-CD20 antibody rituximab in inflammatory autoimmune diseases.
    Tanaka Y
    Intern Med; 2007; 46(16):1313-5. PubMed ID: 17704614
    [No Abstract]   [Full Text] [Related]  

  • 4. Rituximab for Sight-Threatening Lupus-Related Retinal Vasculitis.
    Tselios K; Lam WC; Urowitz MB; Gladman DD
    J Clin Rheumatol; 2018 Mar; 24(2):93-94. PubMed ID: 29059086
    [No Abstract]   [Full Text] [Related]  

  • 5. [B cell targeting therapy using the anti-CD20 antibody in autoimmune diseases].
    Tanaka Y
    Yakugaku Zasshi; 2009 Jun; 129(6):675-9. PubMed ID: 19483410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
    Walsh M; Jayne D
    Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M; Mendoza-Pinto C; Sandoval-Cruz M; Soto-Vega E; Beltran-Castillo A; Jimenez-Hernandez M; Graillet D; Gonzalez L; Rojas-Rodriguez J; Pineda-Almazana A; Zamudio-Huerta L; Lopez-Colombo A
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Retinal vasculopathy in systemic lupus erythematosus: a case of lupus vasculitis and a case of non-vasculitis venous occlusion].
    Figueras-Roca M; Rey A; Mesquida M; Pelegrín L; Llorens V; Fontenla JR; Adán A
    Arch Soc Esp Oftalmol; 2014 Feb; 89(2):66-9. PubMed ID: 24269411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20).
    Eisenberg R
    Endocr Metab Immune Disord Drug Targets; 2006 Dec; 6(4):345-50. PubMed ID: 17214580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rituximab (anti-CD20 monoclonal antibody) for refractory systemic lupus erythematosus: report of one case].
    Sabugo F; Llanos C; Soto L; Gutiérrez J; Cuchacovich M
    Rev Med Chil; 2005 Jun; 133(6):681-4. PubMed ID: 16075133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus.
    Goldblatt F; Isenberg DA
    Handb Exp Pharmacol; 2008; (181):163-81. PubMed ID: 18071946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of retinal vasculitis in Behçet's disease with rituximab.
    Sadreddini S; Noshad H; Molaeefard M; Noshad R
    Mod Rheumatol; 2008; 18(3):306-8. PubMed ID: 18438602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD20 therapy of treatment-resistant Wegener's granulomatosis: favourable but temporary response.
    Omdal R; Wildhagen K; Hansen T; Gunnarsson R; Kristoffersen G
    Scand J Rheumatol; 2005; 34(3):229-32. PubMed ID: 16134730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical, biological and ultrasonographic remission in a patient with musculoskeletal systemic lupus erythematosus with rituximab.
    Torrente-Segarra V; Lisbona-Pérez M; Rotes-Sala D; Castro-Oreiro S; Carbonell-Abelló J
    Lupus; 2009 Mar; 18(3):270-2. PubMed ID: 19213868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibody in acute life threatening haemolytic anaemia complicating childhood onset SLE.
    Abdwani R; Mani R
    Lupus; 2009 Apr; 18(5):460-4. PubMed ID: 19318402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab-induced long-term remission in two children with SLE.
    Jansson AF; Wintergerst U; Renner ED; Belohradsky BH
    Eur J Pediatr; 2007 Feb; 166(2):177-81. PubMed ID: 16915375
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-CD20 therapy for inducing and maintaining remission in refractory systemic lupus erythematosus].
    Chehab G; Sander O; Fischer-Betz R; Schneider M
    Z Rheumatol; 2007 Jul; 66(4):328, 330-6. PubMed ID: 17440741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C; Börjesson-Asp K; Zendjanchi K; Sundqvist AC; Tarkowski A; Bokarewa M
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: an update.
    Hughes G
    Lupus; 2007; 16(7):529-30. PubMed ID: 17670854
    [No Abstract]   [Full Text] [Related]  

  • 20. Successful treatment of refractory immune thrombocytopenia with anti-CD20 antibody in a patient with systemic lupus erythematosus.
    Lee JW; Kim HA; Sung JM; Suh CH
    Lupus; 2010 Feb; 19(2):227-8. PubMed ID: 19884220
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.